• Home
• Our work with communities
• Global health programmes
• Malaria
• Our malaria programmes

Our Malaria Programmes

Despite the prevalence of malaria it can be prevented by controlling the breeding of mosquitoes and using low cost measures such as insecticide-treated nets (ITNs). Malaria can also be treated effectively using inexpensive drugs.

At GSK we are committed to playing a significant role in improving the health of communities affected by malaria in three ways:

• through on-going research into new malaria medicines, treatments and vaccines
• with preferential pricing of our anti-malarials in the least developed countries and sub-Saharan Africa
• through our community investment activities funded by the GSK African Malaria Partnership

GSK’s African Malaria Partnership (AMP)
The AMP was established in 2001 to improve the prevention and treatment of malaria in sub-Saharan Africa. Since then we have invested over US$ 3 million on initiatives to combat the disease.  Initial activities focussed on behavioural change programmes across eight African countries. Such social change is essential to encourage people to sleep under treated bednets and seek treatment for a child with fever. But it is also important to focus attention on the scale of the malaria problem and we are now supporting ‘Mobilising for Malaria’, an advocacy initiative aimed at generating greater awareness, political commitment and sustained funding to combat this disease.

Our community progammes:

Uganda: Getting malaria treatment to communities

West Africa: Giving 'Credit With Education'

Sudan: Behaviour promotion for Malaria prevention and treatment

’Mobilising for Malaria’: A global advocacy support initiative